Prevotella

Roughly half of adults carry almost no Prevotella in their gut at all. The other half carry enormous amounts. In one study of healthy Japanese adults, the genus showed up in 46% of people, and when it did, it was present at very high levels. In everyone else it was undetectable or close to it. This is not a bell curve. It is two populations.

Which group you fall into says something about your diet, your gut ecology, and possibly your risk for a handful of inflammatory and metabolic conditions. What it does not say is whether you are healthy. Prevotella is one of the most argued-about organisms in microbiome science, and the argument is not close to settled.

What This Test Actually Measures

The assay uses PCR (polymerase chain reaction), a technique that amplifies and counts specific stretches of DNA. Here it targets a bacterial gene called 16S ribosomal RNA, which differs enough between bacterial groups to act as a fingerprint. The result reflects how much Prevotella DNA is in your stool sample.

You are counting microbes, not measuring something your own body produces. These bacteria live in the colon, where they ferment plant fibers into short-chain fatty acids like acetate and propionate. So a high number usually reflects two things: how much unrefined plant material you eat, and which microbial community established itself in your gut years ago.

One limit matters more than the others. Standard 16S PCR identifies Prevotella at the genus or species level. It cannot distinguish a harmless fiber-fermenting strain from an inflammatory one. What gets called the single species Prevotella copri is really a set of genetically distinct lineages carrying different metabolic machinery. The number on your report does not tell you which of them you host.

Rheumatoid Arthritis

This is the strongest human association in the literature, and it is striking. Among people with brand-new, untreated rheumatoid arthritis, 75% had expanded Prevotella copri in their stool: 33 of 44 people. Among healthy controls, 11.5%, or 3 of 26. The organism dominated the gut roughly six times as often in the people with early disease.

The signal shows up before diagnosis too. People in pre-clinical stages of rheumatoid arthritis, identified by antibody status and family history rather than joint symptoms, also carry enriched Prevotella. And in immune studies, Prevotella copri proteins trigger T-cell responses in a subset of rheumatoid arthritis patients, which is the kind of mechanistic detail that makes an association harder to dismiss as coincidence.

Still, this is correlation. A cross-sectional study cannot tell you whether the bacteria helped start the disease or expanded because of it. A longitudinal study of people at risk for rheumatoid arthritis found that gut changes may occur late in the process, closer to the onset of joint disease than to its origin. If you have a family history of rheumatoid arthritis or a positive antibody test, a high result here is worth knowing about. It is not a diagnosis and it should not change your treatment on its own.

Liver and Metabolic Disease

At the level of the whole genus, the fatty liver evidence has gone the wrong way. A 2021 meta-analysis of nonalcoholic fatty liver disease reported higher Prevotella in affected people, but the estimate barely cleared statistical significance and spanned everything from a trivial difference to a very large one. A larger 2023 update covering 28 studies and 3,566 people found no significant difference between people with fatty liver and controls. Treat the genus-level link as unproven.

The more specific signal sits below the genus. In Asian cohorts, Prevotella copri enrichment tracks with metabolic dysfunction-associated fatty liver disease, insulin resistance, and higher bacterial production of lipopolysaccharide. Lipopolysaccharide makes up part of the outer wall of certain gut bacteria, and it provokes inflammation when it crosses into the bloodstream. In people with obesity, a gut community dominated by Prevotella copri has also been associated with the inflammatory form of fatty liver disease and with less butyrate-producing capacity. Separate work grouping people by their dominant gut community found that a Prevotella-heavy pattern associated with higher rates of obesity and diabetes. None of this is visible on a genus-level report.

Diet is the obvious confounder and it is a big one. The populations where Prevotella runs highest are rural and non-industrialized, eating unrefined plant starches. The populations where fatty liver disease runs highest are not. Any study that does not carefully separate these is at risk of measuring diet twice and calling it biology once.

Colorectal Cancer, Where the Findings Contradict Each Other

Prevotella copri appears as one of five bacteria in a fecal PCR panel built to detect colorectal cancer. The panel separated people with cancer from people without reasonably well, with an area under the curve of 0.861. That measure runs from 0.5, a coin flip, to 1.0, perfect. Paired with a standard fecal immunochemical test for hidden blood, the bacterial markers caught more cancers than the blood test alone did. A panel like that is a pattern detector, not a claim that this organism drives the tumor. The Prevotella species most often implicated in promoting tumors is Prevotella intermedia, a mouth organism rather than the gut species this test centers on.

Then the direction flips. In a cohort of 333 people who had stool collected before colorectal cancer surgery, a Prevotella-dominant gut community predicted better survival and slower progression, outperforming carcinoembryonic antigen and lymphatic invasion, two markers oncologists rely on routinely.

These two findings are not actually in conflict once you stop treating Prevotella as a good bacterium or a bad one. It is a marker of which ecological pattern your gut has settled into, and different patterns carry different risks for different things. A Prevotella-heavy gut may be more detectable as cancerous when cancer is present, because the whole community shifts, and simultaneously be a gut where established cancer behaves less aggressively. This is the same logic that makes a biomarker useful for diagnosis and useless as a target. Do not read your result as a verdict.

Protection Against Infection

The clearest benefit evidence comes from children, not adults. In a study of 633 rural African children aged 7 to 37 months, stable colonization by Prevotella stercorea tracked with fewer and shorter infections, including substantially fewer diarrheal episodes.

The proposed mechanism is competitive: a well-established fiber-fermenting community occupies the niche and produces the metabolites that keep the gut lining intact, leaving less room for pathogens. Whether any of this transfers to a well-fed adult in a high-income country with clean water is unknown. Read it as evidence that Prevotella is not inherently harmful, not as a reason to try to raise yours.

Kidney and Liver Disease Progression

Loss of Prevotella shows up in the other direction too. In chronic kidney disease, the gut community shifts away from Prevotella and toward Bacteroides, and the fewer butyrate-producing bacteria people carry, the higher their blood C-reactive protein, a standard marker of inflammation. In chronic hepatitis B, depletion of Prevotella tracks with progression toward cirrhosis.

Neither finding establishes cause. Advanced kidney and liver disease change diet, medication exposure, and gut transit enough to reshape the microbiome on their own.

Why a Single Reading Can Fool You

Read this part before you order the test. Prevotella is among the most temporally unstable organisms in the gut. Daily quantitative profiling over six weeks found it swinging by orders of magnitude between consecutive samples from the same person. Three-day consecutive sampling put the within-person variation above 30%.

Four things distort a single result:

• Day-to-day biological swings: this organism fluctuates more than most. One sample is a snapshot of a moving target, not a stable baseline.
• DNA extraction method: across 2,722 samples, the extraction protocol accounted for the largest single source of technical variation in what gets recovered. Two labs can report meaningfully different numbers from the same stool.
• Stool consistency and transit time: water content and how fast material moves through you both correlate with which microbes dominate. A loose sample and a firm sample from the same week can read differently.
• Recent antibiotics and common drugs: in hospitalized older adults the Bacteroides-Prevotella group ran roughly a hundredfold below that of healthy peers at home, and antibiotics pushed it down further. Proton pump inhibitors and analgesics also shift gut composition enough to bias a reading.

There is also a site problem. Prevotella species live in the mouth as well as the gut, and swallowed oral strains travel down the digestive tract. Inflammatory changes in the upper gastrointestinal tract show up in tissue biopsies but not in stool. A normal stool result does not rule out Prevotella-related trouble somewhere else.

Tracking Your Trend

Given how much a single sample moves, the trend is the only part of this test worth much. Get a baseline. If you are changing your diet deliberately, retest in three to six months. After that, annually is a reasonable cadence for anyone tracking gut health seriously.

One caveat on what a trend can actually prove. In a six-month randomized trial of the New Nordic Diet in 62 adults, the Prevotella-to-Bacteroides ratio stayed stable despite a whole-diet overhaul. Your baseline community may be harder to move than the marketing around gut health suggests. If your number does not budge after a year of eating more plants, that is a real finding about your gut, not a failure on your part.

Where trending does earn its keep is in separating signal from noise. A single high reading means little. Three readings over eighteen months that all sit high, taken from the same lab with the same extraction method, mean something. If you are going to track this, use one lab and stick with it.

What To Do With an Unexpected Result

Start by deciding whether the result is real. Repeat it on a different day, ideally several weeks later, from the same lab. If you took antibiotics, a proton pump inhibitor, or had a bout of loose stools in the month before collection, the first number is suspect and the repeat is the one that counts.

If a high reading holds and you have joint pain, morning stiffness, or a family history of rheumatoid arthritis, that combination is worth investigating with rheumatoid factor and anti-CCP antibody testing rather than more microbiome work. A rheumatologist is the right next step if those come back positive. If a high reading holds alongside elevated ALT, high triglycerides, or a fatty liver on imaging, the useful workup is metabolic, not microbial: fasting insulin, HbA1c, and a full lipid panel with ApoB.

If a low or absent reading holds and you are otherwise well, do nothing. Roughly half of healthy adults have almost none. Absence is not deficiency.

One thing this test cannot replace: it is not colorectal cancer screening. If you are due for a colonoscopy or a fecal immunochemical test, get those. The bacterial panels that include Prevotella are research tools that improve detection when added to standard screening, not substitutes for it.

How Mature Is This Test?

It is exploratory. There are no validated reference ranges for stool Prevotella. The strongest causal evidence that exists is mostly in the wrong place, using genetic inference to link a gut Prevotella species to periodontitis risk, which is not what most people ordering this test are worried about. For the systemic conditions people care about most, the evidence is almost entirely observational.

That is an argument for interpreting your result carefully, not for skipping it. If you are going to track your gut over the next decade, having a baseline now from a consistent lab is worth more than starting from scratch in 2030 if the science catches up.